advertisement

---

Singh IP 18

Showing records 1 to 18 | Display all abstracts from Singh IP

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Singh IP
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Ahmed IIK; Rhee DJ
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Fechtner RD
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Jones J
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Myers JS
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Singh IP
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Kim T
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Radcliffe N
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Usner DW; McKee H
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Gazzard G
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Sheng H
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Samuelson TW
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Lewis RA
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Ong J
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Heah T
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Singh K
Ophthalmology 2021; 128: 857-865

---

90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Kopczynski CC
Journal of Glaucoma 2020; 29: 878-884

---

91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract

Ophthalmology 2021; 128: 857-865

---